Deacetylase inhibitors for the treatment of myelodysplastic syndromes

References

• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Myelodysplastic syndromes. 2014. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
   Google Scholar
• Greenberg P. The myelodysplastic syndromes. In: Hoffman R, Benz E, Shattil S, editors. Hematology: basic principles and practice. 3rd ed. New York: Churchill Livingstone; 2000. p. 1106.
   Google Scholar
• Sole F, Espinet B, Sanz GF, et al. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Espanol de Citogenetica Hematologica. Br J Haematol 2000;108:346–356.
   PubMed Web of Science ®Google Scholar
• Corey SJ, Minden MD, Barber DL, et al. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer 2007;7:118–129.
   PubMed Web of Science ®Google Scholar
• Stintzing S, Kemmerling R, Kiesslich T, et al. Myelodysplastic syndrome and histone deacetylase inhibitors: “to be or not to be acetylated”? J Biomed Biotechnol 2011;2011:214143.
   Google Scholar
• Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976;33:451–458.
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting-Airlie house, Virginia, November 1997. J Clin Oncol 1999;17:3835–3849.
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292–2302.
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079–2088.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120:2454–2465.
   PubMed Web of Science ®Google Scholar
• Voso MT, Fenu S, Latagliata R, et al. Revised international prognostic scoring system (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO prognostic scoring system: validation by the Gruppo Romano Mielodisplasie Italian regional database. J Clin Oncol 2013; 31:2671–2677.
   PubMed Web of Science ®Google Scholar
• Khan H, Vale C, Bhagat T, et al. Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes. Semin Hematol 2013;50:16–37.
   PubMed Web of Science ®Google Scholar
• Fandy TE, Herman JG, Kerns P, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009;114:2764–2773.
   PubMed Web of Science ®Google Scholar
• Issa JP. Epigenetic changes in the myelodysplastic syndrome. Hematol Oncol Clin North Am 2010;24:317–330.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kantarjian H, et al.; World Health Organization (WHO) international working group. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000;96:3671–3674.
   PubMed Web of Science ®Google Scholar
• Xu F, Deeg HJ. Current status of allogeneic hematopoietic cell transplantation for MDS. Curr Pharm Des 2012;18:3215–3221.
   PubMed Web of Science ®Google Scholar
• Estey EH, Thall PF, Cortes JE, et al. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood 2001;98:3575–3583.
   PubMed Web of Science ®Google Scholar
• List A, Dewald G, Bennett J, et al.; Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355:1456–1465.
   PubMed Web of Science ®Google Scholar
• Griffiths EA, Gore SD. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin Hematol 2008;45:23–30.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Zulueta M, Bender CM, Yang AS, et al. Methylation of the 5’ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 1995;55:4531–4535.
   PubMed Web of Science ®Google Scholar
• Yoshiura K, Kanai Y, Ochiai A, et al. Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci USA 1995;92:7416–7419.
   PubMed Web of Science ®Google Scholar
• Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 1998;95:6870–6875.
   PubMed Web of Science ®Google Scholar
• Kaminskas E, Farrell A, Abraham S, et al.; FDA. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 2005;11:3604–3608.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al.; International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223–232.
   PubMed Web of Science ®Google Scholar
• Gore SD, Fenaux P, Santini V, et al. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica 2013;98:1067–1072.
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Tiu RV, Komrokji R, et al. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood 2012;120:4945–4951.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106:1794–1803.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, O’Brien S, Huang X, et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 2007;109:1133–1137.
   PubMed Web of Science ®Google Scholar
• Lee YG, Kim I, Yoon SS, et al.; Korean Society of Haematology AML/MDS working party. Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes. Br J Haematol 2013;161:339–347.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Garcia-Manero G, Batty N, et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer 2010;116:3830–3834.
   PubMed Web of Science ®Google Scholar
• Taby R, Issa JP. Cancer epigenetics. CA Cancer J Clin 2010;60: 376–392.
   PubMed Web of Science ®Google Scholar
• Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769–784.
   PubMed Web of Science ®Google Scholar
• Cameron EE, Bachman KE, Myohanen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999;21:103–107.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Yang H, Bueso-Ramos C, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008;111:1060–1066.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Tambaro FP, Bekele NB, et al. Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. J Clin Oncol 2012;30:2204–2210.
   PubMed Web of Science ®Google Scholar
• Silverman LR, Verma A, Odchimar-Reissig R, et al. A phase I trial of the epigenetic modulators vorinostat, in combination with azacitidine (azaC) in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): a study of the New York Cancer Consortium. Blood 2008;112(Suppl. 1): Abstract 3656.
   Google Scholar
• Byrd JC, Marcucci G, Parthun MR, et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005; 105:959–967.
   PubMed Web of Science ®Google Scholar
• Klimek VM, Fircanis S, Maslak P, et al. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin Cancer Res 2008;14:826–832.
   PubMed Web of Science ®Google Scholar
• Kuendgen A, Strupp C, Aivado M, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 2004;104:1266–1269.
   PubMed Web of Science ®Google Scholar
• Kuendgen A, Bug G, Ottmann OG, et al. Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid. Clin Epigenetics 2011;2:389–399.
   PubMed Web of Science ®Google Scholar
• Novotny-Diermayr V, Hart S, Goh KC, et al. The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML. Blood Cancer J 2012;2:e69.
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Kantarjian HM, Ravandi F, et al. Very high rates of clinical and cytogenetic response with the combination of the histone deacetylase inhibitor pracinostat (SB939) and 5-azacitidine in high-risk myelodysplastic syndrome. Blood 2012;120(Suppl. 1): Abstract 3821.
   Google Scholar
• Duvic M, Dummer R, Becker JC, et al. Panobinostat activity in both bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer 2013;49:386–394.
   PubMed Web of Science ®Google Scholar
• Younes A, Sureda A, Ben-Yehuda D, et al. Panobinostat in patients with relapsed/refractory hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol 2012;30:2197–2203.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Alsina M, Weber DM, et al. PANORAMA 2: Panobinostat combined with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma. Blood 2012;120(Suppl. 1): Abstract 1852.
   Google Scholar
• Richardson PG, Hungria VTM, Yoon S, et al. Panorama 1: a randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol 2014;32(5 Suppl.): Abstract 8510.
   Google Scholar
• Deangelo DJ, Spencer A, Bhalla KN, et al. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia 2013;27:1628–1636.
   PubMed Web of Science ®Google Scholar
• Bug G, Burchert A, Kroger N, et al. Phase I/II study of panobinostat following allogenic stem cell transplantation in patients with high risk MDS or AML: initial results from the phase I part of the PANOBEST trial. Presented at EHA Annual Meeting, Stockholm, 2013.
   Google Scholar
• Ottmann OG, DeAngelo DJ, Garcia-Manero G, et al. Determination of a phase II dose of panobinostat in combination with 5-azacitidine in patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia. Blood 2011;118(Suppl. 1): Abstract 459.
   Google Scholar
• Tan P, Wei A, Mithraprabhu S, et al. Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood Cancer J 2014;4:e170.
   PubMed Web of Science ®Google Scholar
• Prebet T, Sun Z, Figueroa ME, et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US leukemia intergroup trial E1905. J Clin Oncol 2014; 32:1242–1248.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007;109:52–57.
   PubMed Web of Science ®Google Scholar